Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Guidance and quality standards
Awaiting development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 active)
Skip to results
Filter by title or keyword
Filter
Area of interest
Area of interest
COVID-19 (9)
Type
(
2 selected
)
Type
Guidance (315)
Quality standard (31)
Guidance programme
Guidance programme
Diagnostics guidance (2)
Health technology evaluations (1)
Highly specialised technologies guidance (1)
Interventional procedures guidance (15)
Medical technologies guidance (7)
Technology appraisal guidance (289)
Apply filters
Showing 151 to 175 of 346
Type: Guidance
Remove Type: Guidance filter
Type: Quality standard
Remove Type: Quality standard filter
Guidance and quality standards awaiting development
Title
Type
Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults TS ID 10652
Technology appraisal guidance
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer TS ID 10203
Technology appraisal guidance
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]
Technology appraisal guidance
Linerixibat for treating pruritus in people with primary biliary cholangitis TS ID 10136
Technology appraisal guidance
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]
Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]
Technology appraisal guidance
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer TS ID 11970
Technology appraisal guidance
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]
Technology appraisal guidance
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]
Technology appraisal guidance
Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]
Technology appraisal guidance
Managing symptoms with an uncertain cause
Quality standard
Masitinib with riluzole for treating amyotrophic lateral sclerosis TS ID 10728
Technology appraisal guidance
Mavorixafor for treating WHIM syndrome ID3946
Technology appraisal guidance
Mepolizumab for treating chronic obstructive pulmonary disease [ID1237]
Technology appraisal guidance
MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400
Technology appraisal guidance
Mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 TS ID 10730
Technology appraisal guidance
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442
Technology appraisal guidance
MRI guided focused ultrasound subthalamotomy in parkinson's disease
Interventional procedures guidance
Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]
Technology appraisal guidance
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]
Technology appraisal guidance
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over TS ID 11777
Technology appraisal guidance
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]
Technology appraisal guidance
Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping TS ID 10593
Technology appraisal guidance
Nipocalimab for treating generalised myasthenia gravis TS ID 11958
Technology appraisal guidance
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer TSID 12044
Technology appraisal guidance
Previous page
1
…
5
6
Current page
7
8
9
…
14
Page
7
of
14
Next page
Results per page
10
25
50
All
Back to top